TW200718693A - Aminopyrimidines as kinase modulators - Google Patents

Aminopyrimidines as kinase modulators

Info

Publication number
TW200718693A
TW200718693A TW095120473A TW95120473A TW200718693A TW 200718693 A TW200718693 A TW 200718693A TW 095120473 A TW095120473 A TW 095120473A TW 95120473 A TW95120473 A TW 95120473A TW 200718693 A TW200718693 A TW 200718693A
Authority
TW
Taiwan
Prior art keywords
compounds
trkb
flt3
kit
aminopyrimidines
Prior art date
Application number
TW095120473A
Other languages
English (en)
Inventor
Michael David Gaul
Guo-Zhang Xu
Christian Andrew Baumann
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of TW200718693A publication Critical patent/TW200718693A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW095120473A 2005-06-10 2006-06-09 Aminopyrimidines as kinase modulators TW200718693A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68971705P 2005-06-10 2005-06-10
US75108405P 2005-12-16 2005-12-16

Publications (1)

Publication Number Publication Date
TW200718693A true TW200718693A (en) 2007-05-16

Family

ID=36929309

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095120473A TW200718693A (en) 2005-06-10 2006-06-09 Aminopyrimidines as kinase modulators

Country Status (17)

Country Link
US (1) US20060281764A1 (zh)
EP (1) EP1896029A1 (zh)
JP (1) JP2008543760A (zh)
KR (1) KR20080028911A (zh)
AR (1) AR053895A1 (zh)
AU (1) AU2006258054A1 (zh)
BR (1) BRPI0611963A2 (zh)
CA (1) CA2611470A1 (zh)
EA (1) EA200800015A1 (zh)
EC (1) ECSP077991A (zh)
GT (1) GT200600248A (zh)
IL (1) IL187693A0 (zh)
NI (1) NI200700316A (zh)
NO (1) NO20080163L (zh)
PE (1) PE20070076A1 (zh)
TW (1) TW200718693A (zh)
WO (1) WO2006135644A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2622372A1 (en) * 2005-09-13 2007-03-22 Palau Pharma, S.A. 2-aminopyrimidine derivatives as modulators of the histamine h4 receptor activity
JP5325783B2 (ja) 2006-09-08 2013-10-23 エフ．ホフマン−ラ ロシュ アーゲー ベンゾトリアゾールキナーゼモジュレーター
WO2008039794A1 (en) * 2006-09-25 2008-04-03 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
JP2010522163A (ja) * 2007-03-20 2010-07-01 キュリス，インコーポレイテッド 亜鉛結合部位を含むＲａｆキナーゼインヒビター
WO2010054185A1 (en) * 2008-11-06 2010-05-14 Ambit Biosciences Corporation Phosphorylated fms-related tyrosine kinase 3 biomarker assay
EP2352730A4 (en) * 2008-11-07 2012-04-25 Lundbeck & Co As H BIOLOGICALLY ACTIVE AMIDES
EP3461824B1 (en) 2009-09-04 2021-08-25 Biogen MA Inc. Bruton's tyrosine kinase inhibitors
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
SG11201900515PA (en) 2016-07-21 2019-02-27 Biogen Ma Inc Succinate forms and compositions of bruton's tyrosine kinase inhibitors
JP6959332B2 (ja) * 2016-09-27 2021-11-02 ミッション セラピューティクス リミティド Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体
CA3056131A1 (en) * 2017-03-16 2018-09-20 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
JP7365347B2 (ja) 2018-02-12 2023-10-19 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレーターおよびその使用
US10696689B2 (en) 2018-09-18 2020-06-30 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
TWI841768B (zh) 2019-08-14 2024-05-11 美商克林提克斯醫藥股份有限公司 非肽生長抑制素(somatostatin)5型受體激動劑及其用途
JP2024506715A (ja) 2021-02-17 2024-02-14 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレーターの結晶形態

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383546A1 (en) * 1999-06-30 2001-01-04 William H. Parsons Src kinase inhibitor compounds
WO2003026665A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors

Also Published As

Publication number Publication date
NO20080163L (no) 2008-03-07
NI200700316A (es) 2009-03-03
KR20080028911A (ko) 2008-04-02
EA200800015A1 (ru) 2008-06-30
JP2008543760A (ja) 2008-12-04
WO2006135644A1 (en) 2006-12-21
GT200600248A (es) 2007-03-14
BRPI0611963A2 (pt) 2010-10-13
AU2006258054A1 (en) 2006-12-21
ECSP077991A (es) 2008-01-23
EP1896029A1 (en) 2008-03-12
AR053895A1 (es) 2007-05-23
PE20070076A1 (es) 2007-02-09
CA2611470A1 (en) 2006-12-21
IL187693A0 (en) 2008-08-07
US20060281764A1 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
TW200716118A (en) Aminopyrimidines as kinase modulators
TW200718693A (en) Aminopyrimidines as kinase modulators
TW200716598A (en) Aminoquinoline and aminoquinazoline kinase modulators
TW200716599A (en) Alkylquinoline and alkylquinazoline kinase modulators
TNSN08278A1 (en) Triazolopyridazines as tyrosine kinase modulators
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
NZ592925A (en) Substituted pyrimidines for the treatment of diseases such as cancer
MY153727A (en) Pyridazinone derivatives
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MX2009013077A (es) Derivados dde benzoxazolona.
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
EA200800011A1 (ru) Тиенопиримидиновые и тиенопиридиновые модуляторы киназы
EA201001596A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
MX2010007927A (es) Derivados de 4-(pirrolo[2,3-c]piridin-3-il)pirimidin-2-ilamina.
MX2009002842A (es) Inhibidores heterociclicos de c-met y usos de los mismos.
MX2011007165A (es) Derivados de piridazinona.
MX2010003563A (es) Inhibidores de proteina cinasa de c-met.
TW200628153A (en) Novel compounds
ATE465165T1 (de) Pyrimidothienindazole als tyrosinkinasehemmer des epidermalen wachstumsfaktors
NO20080160L (no) Mellomprodukter nyttige i syntesene av alkylkinolin og alkylkinazolin kinasemodulatorer og beslektede fremgangsmater for synteser
TW200503722A (en) Substituted 7-aza-quinazoline compounds
MX2010002096A (es) Derivados de tiadiazinona.
MX2011007209A (es) Derivados de piridazinona.